Relation between therapy options for Graves’ disease and the course of Graves’ ophthalmopathy: a systematic review and meta-analysis

Conclusion Radioiodine therapy is a significant risk factor for development or worsening of GO in GD. But GO progression can be prevented by prophylactic glucocorticoids in patients with preexisting GO. Compared with TX alone, TTA induces an earlier and steadier GO improvement in patients with mild to moderate–severe and active GO. Whether this is sufficient to offer TTA to patients needs further investigation.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research